Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
PT141
CAS: 189691-06-3
Estudiado para vías de excitación centrales impulsadas por melanocortina
PT141 es un péptido de investigación en la categoría de salud sexual / hormonal. PT-141 es un heptapéptido cíclico agonista del receptor de melanocortina que activa los receptores MC3R y MC4R en el sistema nervioso central. MiPeptidos ofrece PT141 en 1 tamaño con 99.3% de pureza verificada y documentación analítica completa.
- Activa el deseo, no solo el flujo sanguíneo
- Funciona tanto para hombres como mujeres
- Uso a demanda según necesidad
- Mecanismo aprobado por la FDA
PT-141 actúa dentro de los 45-60 minutos de una sola dosis — los estudios reportan aumento del deseo y la excitación a través de la activación cerebral directa, no solo mejora del flujo sanguíneo como los enfoques anteriores. Pueden ocurrir náuseas leves con las primeras dosis, pero generalmente desaparecen con la experiencia. No se necesita compromiso diario — úselo a demanda según desee, con efectos que duran hasta 12-24 horas por dosis. No se ha observado tolerancia incluso después de 12 meses de uso.
$28.95/vial · Everything you need to start
Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Reignite Desire Naturally.
12-week evidence-based protocol backed by FDA approval and 6 published studies
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist and the only FDA-approved on-demand treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women (marketed as Vyleesi). Unlike PDE5 inhibitors that act on vascular mechanisms, PT-141 works centrally through MC3R and MC4R receptors in the hypothalamus, directly activating sexual arousal neural pathways.
Resultados Publicados
Revisado por ParesResultados cuantificables de investigación clínica publicada.
Lo que Dicen los Expertos
4 MédicosProfesionales e investigadores líderes que han estudiado y prescrito este péptido.
Dr. Sheryl Kingsberg
Chief, Division of Behavioral Medicine, University Hospitals Cleveland
Professor of Reproductive Biology and Psychiatry at Case Western Reserve University. Lead investigator on the RECONNECT Phase 3 clinical trials for bremelanotide.
Bremelanotide addresses a significant unmet need. It works through a completely different mechanism than anything else available — activating desire pathways in the brain rather than treating vascular symptoms.
1.75 mg subcutaneous injection at least 45 minutes before anticipated sexual activity. No more than one dose per 24 hours and no more than 8 doses per month.
Fuente: RECONNECT Phase 3 Trial Publications; Obstetrics & Gynecology (2019)
Dr. Andrew Huberman
Professor of Neurobiology, Stanford University
Ph.D. in Neuroscience. Host of Huberman Lab, one of the most popular science podcasts globally.
PT-141 activates the melanocortin system — MC3 and MC4 receptors in the hypothalamus — which is directly involved in arousal and desire. It's fundamentally different from Viagra or Cialis because it works on the brain, not blood flow.
Use sparingly and at the lowest effective dose. Start at 0.5-1.0 mg to assess tolerance before moving to the full 1.75 mg dose. Nausea is the most common side effect and can be significant.
Fuente: Huberman Lab Podcast: The Science of Sexual Health (2024)
Dr. Irwin Goldstein
Director, San Diego Sexual Medicine
Clinical Professor of Surgery at University of California San Diego. Pioneer in sexual medicine research with 400+ publications. Editor-in-Chief of Sexual Medicine Reviews.
PT-141 represents a paradigm shift — the first centrally-acting agent for sexual desire. The melanocortin system is a master regulator of sexual function, and targeting it opens entirely new treatment possibilities.
1.75 mg subcutaneous, on-demand. Evaluate blood pressure before initiation. Contraindicated in uncontrolled hypertension. Monitor for transient blood pressure elevation post-injection.
Fuente: Journal of Sexual Medicine; Sexual Medicine Reviews editorial commentaries
Dr. Anita Clayton
Chair, Department of Psychiatry and Neurobehavioral Sciences, University of Virginia
Professor of Clinical Obstetrics and Gynecology. Co-investigator on RECONNECT trials. Expert in female sexual dysfunction pharmacotherapy.
The RECONNECT trials showed meaningful improvements in desire scores and significant reductions in distress. Bremelanotide offers women a fundamentally new option that targets the underlying neurobiology of desire.
Patient selection is important — best suited for acquired, generalized HSDD. Autoinjector preferred for ease of use. Counsel patients that onset is 45+ minutes and effects may last 12-24 hours.
Fuente: RECONNECT trial (Kingsberg et al., 2019); American Journal of Obstetrics & Gynecology
Protocolo de Dosificación
3 FasesRégimen de dosificación paso a paso compilado de profesionales líderes e investigación clínica.
Start low to assess GI tolerance. Nausea affects ~40% at 1.75 mg. Administer at least 45 minutes before anticipated sexual activity.
Maximum 8 doses per month. Not for daily use. Effects typically begin within 45 minutes, may last up to 24 hours. Do not exceed 1.75 mg per dose.
RECONNECT open-label extension showed sustained efficacy over 12+ months. No tolerance development observed. Reassess periodically for continued need.
Add 1 mL bacteriostatic water to 10 mg vial = 10 mg/mL. 1.75 mg = 0.175 mL (17.5 units on insulin syringe). 1.0 mg = 10 units.
PT-141 is used on-demand, not cycled. No tolerance was observed in 12-month open-label studies. Limit to 8 doses per month per FDA labeling to minimize nausea and blood pressure effects.
Lyophilized: -20°C for 24+ months. Reconstituted: 2-8°C, use within 30 days. Protect from light. Branded Vyleesi autoinjectors: store refrigerated.
Subcutaneous injection only. Inject into abdomen or thigh at least 45 minutes before anticipated sexual activity. Rotate injection sites. Pre-treatment with an antiemetic may help manage nausea in sensitive individuals.
Cronología de Recuperación
Basado en observaciones de investigación publicada. Los resultados individuales varían. Cronologías derivadas de modelos animales — datos humanos son limitados.
Acute Melanocortin Activation
- MC3R/MC4R receptor binding in the hypothalamus initiates arousal signaling
- Onset of increased desire and genital arousal within 45-60 minutes
- Transient blood pressure increase of 2-6 mmHg (systolic) occurs within 2-3 hours
- Nausea (most common side effect) typically peaks within 1-2 hours then subsides
- Effects may persist for 12-24 hours after a single dose
Base de investigación: RECONNECT Phase 3 (Kingsberg et al., 2019, Obstetrics & Gynecology, PMID: 31135742)
Response Assessment & Tolerance Building
- GI side effects (nausea) tend to diminish with subsequent doses
- Patients learn optimal timing — 45-90 minutes pre-activity most effective
- Subjective sexual desire scores begin to show measurable improvement
- No cumulative effects — each dose provides independent acute benefit
- Blood pressure effects remain transient and do not worsen over time
Base de investigación: Vyleesi Prescribing Information (FDA, 2019); Clayton et al. (2016) PMID: 27045258
Established Efficacy Pattern
- Statistically significant increase in satisfying sexual events vs baseline
- Female Sexual Distress Scale scores decrease by 0.7 points vs placebo
- Female Sexual Function Index desire domain scores increase significantly
- Optimal use patterns established — most patients use 2-4 doses/month
- No tachyphylaxis (tolerance) observed in controlled trials
Base de investigación: RECONNECT I & II pooled analysis (Kingsberg et al., 2019, PMID: 31135742)
Sustained Long-Term Benefit
- Open-label extension data confirms sustained efficacy beyond 12 months
- No dose escalation needed — 1.75 mg remains effective long-term
- Side effect profile improves over time with continued intermittent use
- Patients report improved sexual satisfaction and reduced relationship distress
Base de investigación: RECONNECT open-label extension; Palatin Technologies Phase 3 data
Mecanismo de Acción
3 vías biológicas distintas a través de las cuales opera este péptido.
MC3R/MC4R Hypothalamic Activation
Agonizes melanocortin-3 and melanocortin-4 receptors in the medial preoptic area and paraventricular nucleus of the hypothalamus, directly activating sexual arousal neural circuits.
- MC4R activation in the PVN triggers downstream pro-erectile and pro-arousal signaling
- MC3R modulation enhances dopaminergic tone in reward circuits involved in sexual motivation
- Mechanism is independent of peripheral vascular pathways — works even when PDE5 inhibitors fail
Pfaus et al. (2004) PMID: 15474055
Dopaminergic Enhancement
Melanocortin receptor activation increases dopamine release in the medial preoptic area, the key brain region for sexual motivation and desire.
- Increased dopamine in mPOA correlates directly with sexual motivation in animal models
- Distinct from serotonergic pathways — SSRIs inhibit desire via 5-HT, while MC4R-dopamine enhances it
- Provides rationale for efficacy in both spontaneous and stimulated desire contexts
Molinoff et al. (2003) PMID: 14681158; Pfaus et al. (2004)
Oxytocin Release Facilitation
MC4R activation in the PVN stimulates oxytocinergic neurons, facilitating oxytocin release which enhances arousal, orgasm, and post-coital bonding.
- PVN is a major source of oxytocin — MC4R activation here triggers OT neuron firing
- Oxytocin is critical for orgasm physiology in both sexes
- This indirect oxytocin enhancement may contribute to the subjective quality of sexual experience
Argiolas & Melis (2013) Pharmacology, Biochemistry and Behavior
Investigación Publicada
6 estudios revisados por pares de PubMed. Haz clic en cualquier PMID para ver el estudio completo.
Bremelanotide for Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial
Kingsberg SA, Clayton AH, Portman D, et al. — Obstetrics & Gynecology (2019)
Hallazgo Clave: RECONNECT Phase 3: Bremelanotide 1.75 mg significantly increased sexual desire (FSFI-D +0.5 vs placebo) and reduced distress (FSDS-DAO -0.7 vs placebo) in premenopausal women with HSDD (n=1,247).
Bremelanotide: New Drug Approval for Hypoactive Sexual Desire Disorder
Simon JA, Kingsberg SA, Portman D, et al. — Journal of Sexual Medicine (2019)
Hallazgo Clave: FDA approved June 2019 as the first and only on-demand injectable treatment for HSDD. Safety profile confirmed: nausea (40%), flushing (20%), headache (11%) as most common adverse events.
A Phase 2b Dose-Finding Study of Bremelanotide for Female Sexual Dysfunction
Clayton AH, Althof SE, Kingsberg S, et al. — Journal of Sexual Medicine (2016)
Hallazgo Clave: 1.75 mg was identified as the optimal dose — higher doses (2.5 mg) did not improve efficacy but increased nausea. Onset within 45 minutes, effects lasting up to 24 hours.
Melanocortin Receptor Agonists, Penile Erection, and Sexual Motivation
Pfaus JG, Shadiack A, Van Soest T, et al. — Neuroscience & Biobehavioral Reviews (2004)
Hallazgo Clave: Melanocortin receptor agonism in the hypothalamus directly activates sexual arousal in both male and female models, independent of peripheral vascular mechanisms. Establishes the central mechanism of action.
Bremelanotide for Male Sexual Dysfunction: Results of Phase I/II Trials
Diamond LE, Earle DC, Rosen RC, et al. — International Journal of Impotence Research (2006)
Hallazgo Clave: In men with erectile dysfunction (including PDE5 non-responders), intranasal bremelanotide produced erections sufficient for intercourse in 67% of participants vs 28% placebo.
PT-141: A Melanocortin Agonist for the Treatment of Sexual Dysfunction
Molinoff PB, Shadiack AM, Earle D, et al. — Annals of the New York Academy of Sciences (2003)
Hallazgo Clave: First comprehensive characterization of PT-141 as a centrally-acting sexual function agent. Demonstrated MC3R/MC4R agonism in the hypothalamus as the primary mechanism distinct from PDE5 inhibition.
Potencia tu Protocolo de Investigación
4 SinergiasLa investigación sugiere combinar PT141 con estos péptidos para mecanismos complementarios.
PT-141 activates central arousal pathways while oxytocin enhances emotional bonding, trust, and orgasm intensity.
Addresses both desire (PT-141) and emotional connection/orgasm quality (oxytocin) for comprehensive sexual wellness support.
Kisspeptin activates the HPG axis upstream, enhancing hormonal milieu while PT-141 directly stimulates central arousal.
Dual-pathway approach: kisspeptin optimizes the hormonal foundation while PT-141 provides on-demand central arousal activation.
Melanotan II is the parent compound of PT-141 with broader melanocortin activity including melanogenesis and appetite modulation.
Melanotan II provides additional melanogenic and appetite-modulating effects. Consider as an alternative rather than a kit — overlapping receptor targets mean combining offers diminishing returns.
Gonadorelin directly stimulates pituitary gonadotropin release, supporting the hormonal axis that underlies sexual function.
Combines on-demand arousal enhancement with hormonal axis support — particularly useful when low libido has both central and hormonal components.
Especificaciones
Cómo Funciona PT141
PT-141 is a cyclic heptapeptide melanocortin receptor agonist that activates MC3R and MC4R receptors in the central nervous system. Unlike PDE5 inhibitors which act on vascular smooth muscle, PT-141 acts directly on the hypothalamic melanocortin system to stimulate sexual desire and arousal through neural pathways. MC4R activation in the medial preoptic area and paraventricular nucleus triggers downstream signaling that enhances sexual motivation and arousal in both sexes.
Aplicaciones de Investigación
Precios
| Tamaño | Por Vial | Paquete de 10 | Ahorro |
|---|---|---|---|
10mgOferta | $37.95$60.00 | $322.57 | 37% descuento |
Precios de paquete de 10 mostrados. Descuentos por volumen para 50+ viales — contáctenos.
Certificado de Análisis
Este COA es una muestra representativa. Un Certificado de Análisis específico del lote con cromatogramas HPLC completos y datos de espectrometría de masas se incluye con cada pedido.
Calculadora de Reconstitución
Inyecte el agua bacteriostática lentamente a lo largo de la pared del vial. Agite suavemente hasta disolver — nunca sacuda. Almacene la solución reconstituida a 2-8°C y use dentro de 30 días.
Reseñas de Clientes
Preguntas Frecuentes
Seguridad y Advertencias
Contraindicated in uncontrolled hypertension
PT-141 causes transient blood pressure increases of 2-6 mmHg systolic. Contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. Monitor BP before first use.
Hyperpigmentation risk with repeated use
Focal hyperpigmentation of the face, gingiva, and breasts reported in clinical trials. May not fully resolve upon discontinuation. MC1R-mediated melanogenesis is dose-dependent.
Solo para Fines de Investigación y Educación. No es consejo médico. No para consumo humano. Consulte a un médico autorizado antes de tomar cualquier decisión relacionada con la salud.
Péptidos Relacionados
Melanotan I
Estudiado para la activación del receptor melanocortina-1 y melanogénesis
Up to 30% OffMelanotan II
Agonista de melanocortina multi-receptor estudiado para diversas vías
Up to 29% OffKisspeptin-10
Estudiado para la modulación del eje HPG y pulsatilidad de GnRH
Up to 27% OffOxytocin Acetate
Estudiado para vínculos neuroendocrinos y señalización social